BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

115 related articles for article (PubMed ID: 15906349)

  • 1. Association of the BCRP C421A polymorphism with nonpapillary renal cell carcinoma.
    Korenaga Y; Naito K; Okayama N; Hirata H; Suehiro Y; Hamanaka Y; Matsuyama H; Hinoda Y
    Int J Cancer; 2005 Nov; 117(3):431-4. PubMed ID: 15906349
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The C421A (Q141K) polymorphism enhances the 3'-untranslated region (3'-UTR)-dependent regulation of ATP-binding cassette transporter ABCG2.
    Ripperger A; Benndorf RA
    Biochem Pharmacol; 2016 Mar; 104():139-47. PubMed ID: 26903388
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Association between the ABCG2 C421A polymorphism and Alzheimer's disease.
    Fehér Á; Juhász A; László A; Pákáski M; Kálmán J; Janka Z
    Neurosci Lett; 2013 Aug; 550():51-4. PubMed ID: 23827224
    [TBL] [Abstract][Full Text] [Related]  

  • 4. BCRP gene polymorphisms are associated with susceptibility and survival of diffuse large B-cell lymphoma.
    Hu LL; Wang XX; Chen X; Chang J; Li C; Zhang Y; Yang J; Jiang W; Zhuang SM
    Carcinogenesis; 2007 Aug; 28(8):1740-4. PubMed ID: 17494054
    [TBL] [Abstract][Full Text] [Related]  

  • 5. C421A polymorphism in the human breast cancer resistance protein gene is associated with low expression of Q141K protein and low-level drug resistance.
    Imai Y; Nakane M; Kage K; Tsukahara S; Ishikawa E; Tsuruo T; Miki Y; Sugimoto Y
    Mol Cancer Ther; 2002 Jun; 1(8):611-6. PubMed ID: 12479221
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Breast cancer resistance protein: molecular target for anticancer drug resistance and pharmacokinetics/pharmacodynamics.
    Sugimoto Y; Tsukahara S; Ishikawa E; Mitsuhashi J
    Cancer Sci; 2005 Aug; 96(8):457-65. PubMed ID: 16108826
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Functional SNPs of the breast cancer resistance protein-therapeutic effects and inhibitor development.
    Yanase K; Tsukahara S; Mitsuhashi J; Sugimoto Y
    Cancer Lett; 2006 Mar; 234(1):73-80. PubMed ID: 16303243
    [TBL] [Abstract][Full Text] [Related]  

  • 8. ATP-binding cassette transporter ABCG2 (BCRP) and ABCB1 (MDR1) variants are not associated with disease susceptibility, disease phenotype response to medical therapy or need for surgeryin Hungarian patients with inflammatory bowel diseases.
    Fischer S; Lakatos PL; ; Lakatos L; Kovacs A; Molnar T; Altorjay I; Papp M; Szilvasi A; Tulassay Z; Osztovits J; Papp J; Demeter P; Schwab R; Tordai A; Andrikovics H
    Scand J Gastroenterol; 2007 Jun; 42(6):726-33. PubMed ID: 17505995
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cyclooxygenase-2, multidrug resistance 1, and breast cancer resistance protein gene polymorphisms and inflammatory bowel disease in the Danish population.
    Østergaard M; Ernst A; Labouriau R; Dagiliené E; Krarup HB; Christensen M; Thorsgaard N; Jacobsen BA; Tage-Jensen U; Overvad K; Autrup H; Andersen V
    Scand J Gastroenterol; 2009; 44(1):65-73. PubMed ID: 18819034
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Breast cancer resistance protein (BCRP)-mediated glyburide transport: effect of the C421A/Q141K BCRP single-nucleotide polymorphism.
    Pollex EK; Anger G; Hutson J; Koren G; Piquette-Miller M
    Drug Metab Dispos; 2010 May; 38(5):740-4. PubMed ID: 20159988
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Interindividual variability in the hepatic expression of the human breast cancer resistance protein (BCRP/ABCG2): effect of age, sex, and genotype.
    Prasad B; Lai Y; Lin Y; Unadkat JD
    J Pharm Sci; 2013 Mar; 102(3):787-93. PubMed ID: 23280364
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Genetic and Dietary Regulation of Glyburide Efflux by the Human Placental Breast Cancer Resistance Protein Transporter.
    Bircsak KM; Gupta V; Yuen PY; Gorczyca L; Weinberger BI; Vetrano AM; Aleksunes LM
    J Pharmacol Exp Ther; 2016 Apr; 357(1):103-13. PubMed ID: 26850786
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Association of axitinib plasma exposure and genetic polymorphisms of ABC transporters with axitinib-induced toxicities in patients with renal cell carcinoma.
    Kato H; Sassa N; Miyazaki M; Takeuchi M; Asai M; Iwai A; Noda Y; Gotoh M; Yamada K
    Cancer Chemother Pharmacol; 2016 Oct; 78(4):855-62. PubMed ID: 27586968
    [TBL] [Abstract][Full Text] [Related]  

  • 14. MDM2 SNP309 polymorphism as risk factor for susceptibility and poor prognosis in renal cell carcinoma.
    Hirata H; Hinoda Y; Kikuno N; Kawamoto K; Suehiro Y; Tanaka Y; Dahiya R
    Clin Cancer Res; 2007 Jul; 13(14):4123-9. PubMed ID: 17634539
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Natural allelic variants of breast cancer resistance protein (BCRP) and their relationship to BCRP expression in human intestine.
    Zamber CP; Lamba JK; Yasuda K; Farnum J; Thummel K; Schuetz JD; Schuetz EG
    Pharmacogenetics; 2003 Jan; 13(1):19-28. PubMed ID: 12544509
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Functions of the breast cancer resistance protein (BCRP/ABCG2) in chemotherapy.
    Noguchi K; Katayama K; Mitsuhashi J; Sugimoto Y
    Adv Drug Deliv Rev; 2009 Jan; 61(1):26-33. PubMed ID: 19111841
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The contribution of the ABCG2 C421A polymorphism to cancer susceptibility: a meta-analysis of the current literature.
    Chen P; Zhao L; Zou P; Xu H; Lu A; Zhao P
    BMC Cancer; 2012 Sep; 12():383. PubMed ID: 22937733
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Association of breast cancer resistance protein/ABCG2 phenotypes and novel promoter and intron 1 single nucleotide polymorphisms.
    Poonkuzhali B; Lamba J; Strom S; Sparreboom A; Thummel K; Watkins P; Schuetz E
    Drug Metab Dispos; 2008 Apr; 36(4):780-95. PubMed ID: 18180275
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Genetic Variations in ABCG2 Gene Predict Breast Carcinoma Susceptibility and Clinical Outcomes after Treatment with Anthracycline-Based Chemotherapy.
    Wu H; Liu Y; Kang H; Xiao Q; Yao W; Zhao H; Wang E; Wei M
    Biomed Res Int; 2015; 2015():279109. PubMed ID: 26634205
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Oral sulfasalazine as a clinical BCRP probe substrate: pharmacokinetic effects of genetic variation (C421A) and pantoprazole coadministration.
    Adkison KK; Vaidya SS; Lee DY; Koo SH; Li L; Mehta AA; Gross AS; Polli JW; Humphreys JE; Lou Y; Lee EJ
    J Pharm Sci; 2010 Feb; 99(2):1046-62. PubMed ID: 19569219
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.